Pediatrics During Covid-19 | Children Still Need Their Check-ups! Read More »
Our pediatric offices are open during COVID-19 closures. Your child’s pediatrician is available for you to schedule your child’s next well-check visit and more. Click here to learn more

See Our Other Clinical Research Services:


-About RMC

-Enrolling Research Trials

-Ongoing Research Trials

-Closed Research Trials

-More Information

Closed Research Trials Medical Services are available at the following Riverside Medical Clinic locations:


 

Closed Research Trials

Allergic Rhinitis

Stallergenes: A Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Efficacy and Safety of STG320 Sublingual Tablets of House Dust Mite (HDM) Allergen Extracts in Adults and Adolescents With HDM-associated Allergic Rhinitis.

Rheumatoid Arthritis

R-Pharm: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 2 –

A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy

R-Pharm: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 3 –

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy

R-Pharm:  Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4 –

A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis.

ADHD

Shire: A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Fixed-Dose, Efficacy, and Safety Study of SHP465 in Children Aged 6-12 Years with Attention-Deficit/Hyperactivity Disorder (ADHD).

ADHD

Shire: A Phase 3, Open-label, Multicenter, 12-Month, Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed with Attention-deficit/Hyperactivity Disorder.

Asthma

Pearl Therapeutics:  A Randomized, Double-Blind, Parallel Group, Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistent Asthma.

Sjögrens

Bristol-Myers Squibb:  A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Adults with Active Primary Sjögrens Syndrome.

Infectious Disease

CEM-102 Pharmaceuticals, Inc. / “A Randomized, Double-blind, Multi-center Study To Evaluate the Safety and Efficacy of Oral Sodium Fusidate (CEM-102) Compared to Oral Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure  Infections”


Do NOT follow this link or you will be banned from the site!